

Box Sequence

Ep 1815

Dkt. 0575/50659/JPW/JML

#916  
CJH  
12/10/97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David Baltimore et al.  
Serial No. : 08/813,323 Examiner: Eyler  
Filed : March 10, 1997 Art Unit: 1815  
For : TRUNCATED CRAF1 INHIBITS CD40 SIGNALING

1185 Avenue of the Americas  
New York, New York 10036  
November 25, 1997

Assistant Commissioner for Patents  
Washington, D.C. 20231

DEC 05 1997

SIR:

AMENDMENT IN RESPONSE TO NOVEMBER 12, 1997 COMMUNICATION AND  
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES

This Amendment is submitted in response to the November 12, 1997 Communication issued by the U.S. Patent and Trademark Office in connection with the above-identified application. Applicants attach hereto a copy of the November 12, 1997 Communication and Notice as **Exhibit A**. A response to the November 12, 1997 Communication is due December 12, 1997. Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows:

In the Specification:

Please insert the Sequence Listing, which is submitted herewith as **Exhibit B**, as new pages 40-48, after page 39 of the subject application.

Please renumber originally filed pages 40-52 as new pages 49-61.

Sequence Listing

The Examiner stated that the communication filed on August 4,

David Baltimore et al.  
Serial No.: 08/813,323  
Filed: March 10, 1997  
Page 2

1997 is not fully responsive to the communication mailed on May 30, 1997 for the reasons set forth on the attached Notice to Comply with the Sequence Rules or CRF Diskette Problem Report. The Examiner stated that since the response appears to be bona fide, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is required to complete the response within a time limit of one (1) month from the date of the November 12, 1997 communication or within the time remaining in the response period of the communication mailed May 30, 1997, whichever is the longer.

The Examiner stated that a copy of the "Sequence Listing" in computer readable form has been submitted, however, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked up "Raw Sequence Listing". The Examiner further stated that the computer readable form that has been filed with this application was not saved in ASCII (DOS) text, and was therefore unreadable as indicated on the attached CRF Diskette Problem Report, and that a substitute form must be submitted as required by 37 C.F.R. 1.825(d).

Applicants submit herewith the Sequence Listing on the enclosed computer diskette, which has the same content as the paper copy attached as **Exhibit B**. Applicants submit as **Exhibit C**, a Statement in accordance with 37 C.F.R. §1.821(f) certifying that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) and submitted in connection with the above-identified application, has the same information which is submitted in this amendment to subject application under the section entitled "Sequence Listing" (**Exhibit B**).


If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned

David Baltimore et al.  
Serial No.: 08/813,323  
Filed: March 10, 1997  
Page 3

attorney invites the Examiner to telephone him at the number provided below.

No fee, is deemed necessary in connection with the filing of this Amendment. However, if any additional fee is required, authorization is given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White  
Registration No. 28,678  
Attorney for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231.



11/25/97

John P. White  
Reg. No. 28,678

Date